Compare LNSR & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LNSR | SAVA |
|---|---|---|
| Founded | 2004 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Electronics | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 142.0M | 156.5M |
| IPO Year | N/A | N/A |
| Metric | LNSR | SAVA |
|---|---|---|
| Price | $11.45 | $2.12 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $15.00 | $5.00 |
| AVG Volume (30 Days) | 44.5K | ★ 993.1K |
| Earning Date | 02-26-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $59,141,000.00 | N/A |
| Revenue This Year | $19.55 | N/A |
| Revenue Next Year | $35.89 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.02 | N/A |
| 52 Week Low | $7.25 | $1.15 |
| 52 Week High | $17.31 | $4.98 |
| Indicator | LNSR | SAVA |
|---|---|---|
| Relative Strength Index (RSI) | 47.37 | 36.39 |
| Support Level | $11.19 | $1.96 |
| Resistance Level | $11.81 | $2.16 |
| Average True Range (ATR) | 0.31 | 0.16 |
| MACD | -0.08 | -0.03 |
| Stochastic Oscillator | 18.61 | 16.83 |
LENSAR Inc is a commercial-stage medical device company focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts. The company Laser System incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, simplified procedure planning, efficient design, and precision. Its product portfolio consists of the LENSAR Laser System with Streamline IV and IntelliAxis and its associated consumable components. Geographically, the company generates the majority of its revenue from the United States, followed by Europe and Asia.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.